In Guinea-Bissau, a controversial hepatitis B vaccine trial that aimed to involve 14,000 newborns faced harsh criticism from the World Health Organization (WHO). This trial, funded by the US and led by Danish researchers, was designed to evaluate the broader health effects of the hepatitis B vaccine. However, the WHO expressed significant concerns, labeling the approach as unethical, particularly because it proposed giving some newborns a placebo while providing the treatment to others when a proven effective vaccine already exists. The WHO highlighted that the birth-dose hepatitis B vaccine is not just essential; it has a proven track record in preventing mother-to-baby transmission in up to 95% of cases. Furthermore, it advocates for all newborns to receive this vaccine within 24 hours of birth, as vaccination can dramatically reduce chronic hepatitis B cases. Currently, in Guinea-Bissau, the hepatitis B vaccine is administered at six weeks, but there are plans to roll out the birth-dose nationwide by 2028 to align with global recommendations. The project faced a public backlash, leading to its suspension by the Guinea-Bissau government due to growing outrage and ethical concerns voiced by local health officials, including the former health minister, Magda Robalo. These developments reflect broader tensions regarding the ethics of clinical trials in vulnerable populations, particularly in developing nations. Critics argue that such trials exploit marginalized communities when effective interventions already exist. This situation also highlights the debate surrounding vaccine acceptance and hesitation, particularly in contexts influenced by figures like Robert F. Kennedy Jr., who has promoted controversy around vaccine safety despite claims of being pro-vaccination. The WHO's condemnation of the trial has added to ongoing discussions about vaccination, ethics in research, and the standards to which international health initiatives should be held, especially in regions facing significant health challenges like Guinea-Bissau where more than 12% of the adult population is chronically infected with hepatitis B.